Holm PS - Search Results

1

Selection and characterization of a high-activity ribozyme directed against the antineoplastic drug resistance-associated ABC transporter BCRP/MXR/ABCG2.

Kowalski P, Wichert A, Holm PS, Dietel M, Lage H. Kowalski P, et al. Among authors: holm ps. Cancer Gene Ther. 2001 Mar;8(3):185-92. doi: 10.1038/sj.cgt.7700294. Cancer Gene Ther. 2001. PMID: 11332989

2

Selection of a high activity ribozyme against cytostatic drug resistance-associated glypican-3 using an in vitro assay containing total tumor RNA.

Wichert A, Holm PS, Dietel M, Lage H. Wichert A, et al. Among authors: holm ps. Cancer Gene Ther. 1999 May-Jun;6(3):263-70. doi: 10.1038/sj.cgt.7700045. Cancer Gene Ther. 1999. PMID: 10359212

3

Kinetic characterization of ribozymes directed against the cisplatin resistance-associated ABC transporter cMOAT/MRP2/ABCC2.

Materna V, Holm PS, Dietel M, Lage H. Materna V, et al. Among authors: holm ps. Cancer Gene Ther. 2001 Mar;8(3):176-84. doi: 10.1038/sj.cgt.7700293. Cancer Gene Ther. 2001. PMID: 11332988

4

Reversion of multidrug resistance in the P-glycoprotein-positive human pancreatic cell line (EPP85-181RDB) by introduction of a hammerhead ribozyme.

Holm PS, Scanlon KJ, Dietel M. Holm PS, et al. Br J Cancer. 1994 Aug;70(2):239-43. doi: 10.1038/bjc.1994.286. Br J Cancer. 1994. PMID: 7914421 Free PMC article.

5

Glypican-3 is involved in cellular protection against mitoxantrone in gastric carcinoma cells.

Wichert A, Stege A, Midorikawa Y, Holm PS, Lage H. Wichert A, et al. Among authors: holm ps. Oncogene. 2004 Jan 29;23(4):945-55. doi: 10.1038/sj.onc.1207237. Oncogene. 2004. PMID: 14661052

6

Regulation of MDR1 gene expression in multidrug-resistant cancer cells is independent from YB-1.

Kaszubiak A, Kupstat A, Müller U, Hausmann R, Holm PS, Lage H. Kaszubiak A, et al. Among authors: holm ps. Biochem Biophys Res Commun. 2007 May 25;357(1):295-301. doi: 10.1016/j.bbrc.2007.03.145. Epub 2007 Apr 2. Biochem Biophys Res Commun. 2007. PMID: 17418094

7

Overcoming the classical multidrug resistance phenotype by adenoviral delivery of anti-MDR1 short hairpin RNAs and ribozymes.

Kaszubiak A, Holm PS, Lage H. Kaszubiak A, et al. Among authors: holm ps. Int J Oncol. 2007 Aug;31(2):419-30. Int J Oncol. 2007. PMID: 17611700

8

Multidrug-resistant cancer cells facilitate E1-independent adenoviral replication: impact for cancer gene therapy.

Holm PS, Lage H, Bergmann S, Jürchott K, Glockzin G, Bernshausen A, Mantwill K, Ladhoff A, Wichert A, Mymryk JS, Ritter T, Dietel M, Gänsbacher B, Royer HD. Holm PS, et al. Cancer Res. 2004 Jan 1;64(1):322-8. doi: 10.1158/0008-5472.can-0482-2. Cancer Res. 2004. PMID: 14729641

9

Holm PS, Dietel M, Krupp G. Holm PS, et al. Gene. 1995 Dec 29;167(1-2):221-5. doi: 10.1016/0378-1119(95)00709-1. Gene. 1995. PMID: 8566781

10

[YB-1 as a potential target in cancer therapy].

Lage H, Surowiak P, Holm PS. Lage H, et al. Among authors: holm ps. Pathologe. 2008 Nov;29 Suppl 2:187-90. doi: 10.1007/s00292-008-1030-2. Pathologe. 2008. PMID: 18773210 Review. German.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

58 results

Search Page

Filters